Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE)

Marie-Line Menard, Susanne Thümmler, Marianna Giannitelli, Bertrand Olliac, Olivier Bonnot, David Cohen, Florence Askenazy, ETAPE Study group, Boublil Michel, Castaings Agnès, Chambry Jean, Charvet Dorothée, Cseterky Mona, Fontas Eric, Fourneret Pierre, Gicquel Ludovic, Kabuth Bernard, Leroy Bernard, Maria Fanny, Moceri Pamela, Raynaud Jean-Philippe, Roche Jean-François, Rochet Thierry, Marie-Line Menard, Susanne Thümmler, Marianna Giannitelli, Bertrand Olliac, Olivier Bonnot, David Cohen, Florence Askenazy, ETAPE Study group, Boublil Michel, Castaings Agnès, Chambry Jean, Charvet Dorothée, Cseterky Mona, Fontas Eric, Fourneret Pierre, Gicquel Ludovic, Kabuth Bernard, Leroy Bernard, Maria Fanny, Moceri Pamela, Raynaud Jean-Philippe, Roche Jean-François, Rochet Thierry

Abstract

Introduction: In France, over recent years, the prescription rate of antipsychotic (AP) remained stable in children and adolescents. Prescription of second-generation antipsychotics increased, whereas prescription of first-generation antipsychotics decreased. Off-label prescriptions are very frequent in this population. Adverse events (AEs) in youth treated with AP are common and may be severe. AEs have hitherto been poorly monitored in naturalistic studies independent from industry.

Method and analysis: We describe a French prospective multicentre study in an AP-naïve paediatric population named Etude de la Tolérance des AntiPsychotique chez l'Enfant (ETAPE). The study started in April 2013. So far, 200 patients have been included. The inclusion criteria are: male or female inpatients aged from 6 to 18 years, treated with an AP drug for less than 28 days, never been treated or having received AP for less than 3 months, discontinued at least 6 months prior to inclusion. These assessments of AE are performed at inclusion, as well as at 3, 6, 9 and 12 months after the introduction of the AP. The monitoring period will end in May 2016.

Ethics and dissemination: The study protocol was approved by the Ethics Committee 'Sud Méditerrané V' (number 12.082) and by the French National Agency for Medicines and Health Products Safety (number 2012-004546-15). All patients and their parents signed informed consent on enrolment in the study. We will submit the results of the study to relevant journals and offer national and international presentations. This study will enable better characterisation of the prescription of AP drugs. The results will further help to develop quality standards and recommendations for monitoring AE during the prescription of AP.

Trial registration number: NCT02007928.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Gantt diagram of the ETAPE study. ANSM, French National Agency for Medicines and Health Products Safety; ETAPE, Etude de la Tolérance des AntiPsychotique chez l'Enfant.
Figure 2
Figure 2
Inclusion per centre. Legend of figure 2: Less than 6 inclusions per centre (Fondation Vallée, Gentilly; Nancy University Hospital; Poitiers University Hospital; Monaco Hospital) N=12 (6%).

References

    1. Verdoux H, Pambrun E, Cortaredona S et al. . Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry 2015;24:1181–91. 10.1007/s00787-014-0668-y
    1. Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry 2015;72:867–74. 10.1001/jamapsychiatry.2015.0500
    1. Acquaviva E, Peyre H, Falissard B et al. . Panorama de la prescription et de la consommation des psychotropes chez l'enfant et l'adolescent en France. Neuropsychiatr Enf Adolesc 2012;60:77–85.
    1. Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care 2012;26:139–45. 10.1016/j.pedhc.2011.10.009
    1. Ben Amor L. Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord 2012;138:S22–30. 10.1016/j.jad.2012.02.030
    1. Vitiello B, Correll C, Zwieten-Boot B et al. . Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmocol 2009;19:629–35. 10.1016/j.euroneuro.2009.04.008
    1. Kalverdijk LJ, Tobi H, Van den Berg PB et al. . Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 2008;59:554–60. 10.1176/ps.2008.59.5.554
    1. Zito JM, Safer DJ, de Jong-van den Berg LT et al. . A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26 10.1186/1753-2000-2-26
    1. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 2007;23:49–56. 10.1185/030079906X158075
    1. Jensen PS, Buitelaar J, Pandina GJ et al. . Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16:104–20. 10.1007/s00787-006-0580-1
    1. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev 2011;31:465–71. 10.1016/j.cpr.2010.11.005
    1. Doey T, Handelman K, Seabrook JA et al. . Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 2007;52:363–8.
    1. Cooper WO, Arbogast PG, Ding H et al. . Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006;6:79–83. 10.1016/j.ambp.2005.11.002
    1. Auby P. Nouveaux enjeux de la recherche clinique en psychopharmacologie chez l'enfant et l'adolescent. Neuropsychiatr Enfance Adolesc 2012;60:62–8. 10.1016/j.neurenf.2011.04.007
    1. Cohen D. Les antipsychotiques atypiques chez l'adolescent : quels enjeux pour l'avenir ? Encéphale 2011;37:15–17. 10.1016/S0013-7006(11)70028-8
    1. Arango C, Giraldez M, Merchan-Naranjo J et al. . Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. JAACAP 2014;53:1179–90.
    1. Merchán-Naranjo J, Tapia C, Bailón C et al. . Secondary effects of antipsychotic treatment in naïve or quasi naïve children and adolescents: design of a follow-up protocol and baseline results. Rev Psiquiatr Salud Ment 2012;5:217–28. 10.1016/j.rpsm.2012.03.006
    1. San L, Arranz B, Perez V et al. . One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naïve patients with a first-episode psychosis. Psychiatry Res 2012;200:693–701. 10.1016/j.psychres.2012.07.005
    1. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008;20:195–201. 10.1080/09540260801889179
    1. Cohen D, Bonnot O, Bodeau N et al. . Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian metaanalysis. J Clin Psychopharmacol 2012;32:309–16. 10.1097/JCP.0b013e3182549259
    1. Fraguas D, Correll CU, Merchán-Naranjo J et al. . Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011;21:621–45. 10.1016/j.euroneuro.2010.07.002
    1. Woods SW, Martin A, Spector SG et al. . Effects of development on olanzapine associated adverse events. J Am Acad Child AdolescPsychiatry 2002;41:1439–46. 10.1097/00004583-200212000-00015
    1. Keinänen J, Mantere O, Kieseppä T et al. . Early insulin resistance predicts weight gain and waist circumference increase in first-episode psychosis—a one year follow-up study. Schizophr Res 2015;169:458–63.
    1. Druyts E, Eapen S, Wu P et al. . The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev 2014;3:116 10.1186/2046-4053-3-116
    1. Pina-Camacho L, Díaz-Caneja C, Saiz PA et al. . Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description. Rev Psiquiatr Salud Ment 2014;7:166–78. 10.1016/j.rpsm.2014.05.004
    1. Raffin M, Giannitelli M, Consoli A et al. . Management of adverse effects of second-generation antipsychotics in youth. Current Treatment Options in Psychiatry 2014;1:84–105. 10.1007/s40501-013-0007-9
    1. Rani FA, Byrne PJ, Murray ML et al. . Paediatric atypical antipsychotic monitoring safety (PAMS) study. Pilot study in children and adolescents in secondary and tertiary care settings. Drug Saf 2009; 32:325–33.
    1. Bonnot O, Inaoui R, Raffin-Viad M et al. . Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment. J Child Adolesc Psychopharmacol 2011;21:1–5.
    1. Nielsen RE, Laursen MF, Vernal DL et al. . Risk of diabetes in children and adolescents exposed to antipsychotics: a Nationwide 12-year case-control study. J Am Acad Child Adolesc Psychiatry 2014;53:971–9. 10.1016/j.jaac.2014.04.023
    1. Morrato EH, Nicol GE, Maahs D et al. . Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010;164:344–51. 10.1001/archpediatrics.2010.48
    1. Pringsheim T, Panagiotopoulos C, Davidson J et al. . Des recommandations probantes pour surveiller l'innocuité des antipsychotiques de deuxième génération chez les enfants et les adolescents. Paediatr Child Health 2012;17:12B–21B.
    1. Ho J, Pangiotopoulos C, McCrindle B et al. . Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 2011;20:3 10.1007/s00787-010-0139-z
    1. Persico AM, Arango C, Buitelaar JK et al. . Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. European Neuro Psycho Pharmacology 2015;25:1513–31. 10.1016/j.euroneuro.2015.06.009
    1. Menard ML, Thümmler S, Auby P et al. . Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. Child Adolesc Psychiatry Ment Health 2014;8:18 10.1186/1753-2000-8-18
    1. Menard ML, Askenazy F. Evaluation de l'incidence des événements indésirables sous antipsychotique en population pédiatrique naïve (Étude ETAPE: étude de la tolérance des antipsychotiques chez l'enfant). Neuropsychiatrie de l'Enfance et de l'Adolescence 2013;61:131–2. 10.1016/j.neurenf.2013.01.004
    1. Guy W. ECDEU. Assessment manuel for psychopharmacology: revised (DHEW publication number ADM 76-338). Rockville, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976a:534–7.
    1. Lejoyeux M, Gorwood P, Stalla-Bourdillon A et al. . Traduction et utilisation de l’échelle de Simpson et Angus de symptômes extra-pyramidaux. Encéphale 1993;19:17–21.
    1. Simpson GM, Angus JWS. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 1970;212:11–19. 10.1111/j.1600-0447.1970.tb02066.x
    1. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychol 1989;154:672–6. 10.1192/bjp.154.5.672
    1. Bush G, Fink M, Petrides G et al. . Catatonia.I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129–36. 10.1111/j.1600-0447.1996.tb09814.x
    1. Kaufman J, Birmaher B, Brent D et al. . Schedule for affective disorders and schizophrenia for school age children. Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36:980–8.
    1. Sheehan DV, Lecrubier Y, Harnett Sheehan K et al. . The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232–41. 10.1016/S0924-9338(97)83297-X
    1. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry 2007;7:7 10.1186/1471-244X-7-7
    1. Guy W. ECDEU. Assessment manuel for psychopharmacology. Revised 1976.
    1. Endicott J, Spitzer RL, Fleiss JL. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766–71. 10.1001/archpsyc.1976.01770060086012
    1. Dugas M, Halfon O, Cousin R. Double-blind study of mianserin, imipramine and placebo in childhood depression. Poster presented at the annual meeting of the American Academy of Child and Adolescent Psychiatry; New York, 11-15 October 1989.
    1. March J, Karayal O, Chrisman A. CAPTN: the Pediatric Adverse Event Rating Scale. In: Novins DK, DeYoung, eds. The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 23-28 october 2007; Boston, 2007:241.
    1. Johnson WG, Grieve FG, Adams CD et al. . Measuring binge eating in adolescents: adolescent and parent versions of the Questionnaire of Eating and Weight Patterns. Int J Eat Disord 1999;26:301–14. 10.1002/(SICI)1098-108X(199911)26:3<301::AID-EAT8>;2-M
    1. Kermarrec S, Kabuth B, Bursztejn C et al. . French adaptation and validation of the Helping Alliance Questionnaires for child, parents and therapist. Can J Psychiatry 2003;51:913–22.
    1. Luborsky L. Helping alliances in psychotherapy: the groundwork for a study of their relationship to its outcome. In: Claghorn JL, ed. Successful psychotherapy. New York: Brunner/Mazel, 1976:92–116.
    1. Leon AC, Shear MK, Portera L et al. . Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78–82. 10.1007/BF00788510
    1. Dennison BA, Straus JH, Mellits DE et al. . Childhood physical fitness test: predictor of adult physical activity levels? Pediatrics 1988;82:324–30.
    1. Cohen D, Nicolas JD, Flament MF et al. . Clinical relevance of chronic catatonia schizophrenia in children and adolescents: evidence from a prospective naturalistic study. Schizophr Res 2005;76:301–8. 10.1016/j.schres.2005.01.014

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner